Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, has received an award of public funding to further establish methods for the combination of Affilin® therapeutics with biological effectors. The Investitionsbank Sachsen Anhalt has provided the Company with €700K to fund relevant in-house research projects.
Dr. Ulrike Fiedler, CEO of Scil Proteins, commented: “We are very pleased that the Investitionsbank Sachsen Anhalt has decided to continue and expand their support for our research endeavors to further develop our Affilin® therapeutics. The Bank has seen what we’ve achieved and that there’s significant potential for the development of the technology.”
Scil Proteins’ Affilin® therapeutics are so called scaffold proteins derived from the human serum protein Ubiquitin. Affilin® molecules are high affinity binders with excellent target specificity. The Affilin® platform has successfully delivered target specific molecules, which have subsequently shown activity in animal models, within only a few months. Scil Proteins intends to advance into clinical development two Affilin® therapeutic candidates targeting cancer indications.
Scil Proteins is a biopharmaceutical company discovering and developing Affilin® molecules and working with industry partners in the development and manufacture of protein therapeutics and diagnostics. Affilin® molecules are therapeutics and diagnostics based on a scaffold derived from the human protein Ubiquitin to form highly stable molecules with strong binding specificity and low immunogenicity. Scil Proteins’ discovery platform is a fully patent protected screening technology for the identification of target-specific Affilin® molecules using advanced selection systems.
Scil Proteins has generated a pipeline of Affilin® therapeutics targeting cancer and other therapeutic areas. It also offers the technology to industry for collaborative discovery and development partnerships. With a longstanding expertise in protein production and development, Scil Proteins also offers GMP contract biomanufacturing and process development to biotech and pharma companies. Scil Proteins is a well-established private company located in Halle, Germany.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
